Research Corner: Health Disparities Focus Group
By Dorothy Reed, Chair, Community Cancer Action Board
Palliative Medicine and Supportive Care Program
.divTable{
display: table;
width: 100%;
}
.divTableRow {
display: table-row;
}
.divTableHeading {
background-color: #EEE;
display: table-header-group;
}
.divTableCell, .divTableHead {
display: table-cell;
padding: 3px 10px;
height: auto;
width: 50%;
}
.divTableBody {
display: table-row-group;
}
CAR T-Cell Therapy Available at Rutgers Cancer Institute and Robert Wood Johnson University Hospital
Between 60 to 70 percent of patients with aggressive non-Hodgkin lymphoma are cured with initial chemotherapy and a significant percentage of patients who relapse are cured with a stem cell transplant using the patient’s own cells. However, in patients whose disease becomes resistant to chemotherapy, the average survival is only six months. Until recently, those with B-cell lymphomas that did not respond to standard therapies had limited treatment options.
LGBTQ Health
.program-container {
background-color: #e8f6fb;
padding: 10px;
color: #000000;
}
.program-title {
font: bold 20px Arial,sans-serif;
color: #1B7094;
}
Educational Program Offerings
- Prevention and Early Detection of HPV-Related Cancers for the LGBTQ Community
Cervical Health Awareness Month 2022
Cervical Health Resource Center
January is Cervical Health Awareness Month. Visit our Cervical Health Resource Center for interviews and information on risk factors, screening, and treatment of cervical cancer. Learn more